ThromboGenics' Jetrea recommended for reimbursement by UK's National Institute for Health and Care Excellence.
M2 EQUITYBITES-September 4, 2013-ThromboGenics' Jetrea recommended for reimbursement by UK's National Institute for Health and Care Excellence(C)2013 M2 COMMUNICATIONS http://www.m2.com
Integrated biopharmaceutical company, ThromboGenics' new Jetrea (ocriplasmin) treatment is recommended for reimbursement by the UK's National Institute for Health and Care Excellence in its Final Appraisal Determination, it was reported yesterday.
According to the company, the reimbursement will be conducted within the National Health Service in England and Wales.
Jetrea treats vitreomacular traction and macular hole and was recommended for reimbursement, for treatment of patients showing symptoms of metamorphopsia, whose impact is considered severe and distressing, and equal to loss of two lines in visual acuity.
((Comments on this story may be sent to email@example.com))